Integrated Financial for year ended on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
By the next day the stock moved 3.6 pts more than Nifty Microcap 250 and 5.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lalchandani Labs Ltd filed its audited standalone financial results for FY25 along with the half-year ended March 31, 2025. Revenue from operations stood at Rs. 208.33 lacs, almost flat compared to Rs. 208.38 lacs in FY24, while total revenue was Rs. 233.21 lacs. Profit after tax declined to Rs. 36.51 lacs from Rs. 41.47 lacs in the previous year, with basic EPS at Rs. 0.86 vs Rs. 0.96. The auditor issued a Qualified Opinion, flagging that the company's accounts with lenders are classified as NPA, no working capital limit was sanctioned or renewed, there were defaults in repayment of term loans and unsecured loans, statutory dues such as PF, ESIC, and TDS were unpaid, and gratuity/leave encashment liabilities were not provided for as required by AS-15. The company booked an exceptional gain of Rs. 12.13 lacs from a One Time Settlement (OTS) with banks and NBFCs, though cash and equivalents stood at Rs. 329.73 lacs against short-term borrowings of Rs. 406.71 lacs.
Despite the positive OTS-related exceptional gain, the qualified audit opinion, NPA status with lenders, unpaid statutory dues, and missed provisioning for employee benefits point to serious financial governance and liquidity concerns. Shareholders should view this as a red flag even though the company technically remains profitable on paper.